Serial quantitative liver function tests in patients with primary biliary cirrhosis: A prospective long-term study

Digestion

Volumn 58, Issue 4, 1997, Pages 396-401

  Schonfeld J V ^a   Brener, N ^a   Zotz, R B ^a   Beste, M ^a   Goebell, H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Liver; Primary biliary cirrhosis; Quantitative liver function tests; Ursodeoxycholic acid

Indexed keywords

BILE ACID; GALACTOSE; INDOCYANINE GREEN; LIDOCAINE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; FOLLOW UP; HALF LIFE TIME; HUMAN; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; MORTALITY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; CHOLAGOGUES AND CHOLERETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0030840432     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201472     Document Type: Article

References (27)

1. Kaplan MM: Primary biliary cirrhosis. N Engl J Med 1996;335:1570-1580.
2. Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Damis F: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;i:834-836.
3. Lindor KD, Dickson FR, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, Lesage G, Rossi SS, Hofmann AF: Hrsodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-1290.
4. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC Study Group: Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-1347.
5. Poupon RE, Balkau B, Eschwege E, Poupon R, and the UDCA-PBC Study Group: A multicenter. controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
6. Leuschner U, Fischer H, Kurtz W, Güldütüna S, Hübner K, Hellstem A, Gatzen M, Leusch-ner M: Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial. Gastroenterology 1989:97:1268-1274.
7. Hcathcote EJ, Cauch-Dudck K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michicletti P, Minuk GY, Pappas SC, Scully LJ, Steinbrccher UP, Sutherland LR, Williams CN, Witt-Sulli-van H, Worobetz LJ, Milner RU, Wanless IR: The Canadian multiccnter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994:19:1149-1156.
8. Heathcote EJ, Lindor KD, Poupon R, Cauch-Dudck K, Dickson ER, Trout R, Poupon RE: Combined analysis of French. American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995:108:A 1082.
9. Wiesner RH, Porayko MK, Dickson ER, Gores GJ, LaRusso NF, Hay JE, Wahlstrom HE, Krotn RAF: Selection and timing of livertrans-plantation in primary' biliary cirrhosis and primary sclerosing cholangitis. Hepatology 1992; 16:1290-1299.
10. Consensus statement on indications for liver transplantation: Paris, June 22-23. 1993. Hepatology 1994;20:63s-68s.
11. Christensen E, Altman DG, Neubcrger J, de Stavola BL, Tygstrup N, Williams R, and the PBC1 and PBC2 Trial Groups: Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. Gastroenterology 1993;105:1865-1876.
12. Merkel C, Gatta A, Zoli M, Bolognesi M, Ange-li P, Iervesc T, Marchcsini G, Ruol A: Prognostic value of galactose elimination capacity, ami-nopyrine breath test and ICG clearance in patients with cirrhosis. Dig Dis Sei 1991:36: 1197-1203.
13. Ranck L, Andreasen PB, Tygstrup N: Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976:17:959-964.
14. Oellerich M, Burdelski M, Ringe B, Lamesch P, Gubcrnatis G, Bunzendahl H, Pichlmayr R, Herrmann H: Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989;i:640-642.
15. Oellerich M, Burdelski M, Lautz HU, Rodeck B, Duewel J, Schulz M, Schmidt FW, Brodchl J, Pichlmayr R: Assessment of prelransplant prognosis in patients with cirrhosis. Transplantation 1991;51:801-806.
16. v Schönfeld J, Breuer N, Zotz R, Liedmann H, Weneker M, Beste M, Konietzko N, Goebell H: Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (Pi ZZ). Digestion 1996:57:165-169.
17. Zotz R, Schönfeld J, Erhard J, Breuer N, Lange R, Beste M, Eigler FW, Goebell H: Value of an extended MF.GX formation test and other dynamic liver function tests in liver transplant donors. Transplantation 1997:63:538-541.
18. Tygstrup N: Determination of the hepatic elimination capacity of galactose by single injection. Scand J Clin Lab Invest 1966:92(suppl 18):118-125.
19. Lerman A, Hildebrand FL, Margulies KB, O'Murchu B, Perrella MA, Heublein DM, Schwab TR, Burnett JC: Endothelin: a new cardiovascular regulatory peptide. Mayo Clinic Proc 1990:65:1441-1455.
20. Meijcr DKF, Weert B, Vermeer GA: Pharmacokinetics of biliary excretion in man. VI. Indo-cvanine green. Eur J Clin Pharmacol 1988:35: 295-303.
21. Huet PM, Villcneuve JP: Determinants of drug disposition in patients with cirrhosis. Hepato-logy 1983:3:913-918.
22. Leuschner U, Giilduluna S, Inthof M, Hiibner K, Benjaminov A, Leuschner M: Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994;21:624-633.
23. Vaubourdolle M, Guflflet V, Chazouillercs O, Giboudeau J, Poupon R: Indocyaninc grcen-sulfobromophthalcin pharmacokinetics for diagnosing primary biliary cirrhosis and assessing histological severity. Clin Chem 1991;37: 1688-1690.
24. Loiterer E, Stiehl A, Raedsch R, Foclsch UR, Bircher J: Ursodeoxycholic acid in primary biliary cirrhosis: No evidence for toxicity in the stages I to III. J Hepatol 1990:10:284-290.
25. Clements D, Elias E, McMaster P: Preliminary study of indocyanine green clearance in primary biliary cirrhosis. Scand J Gastroenterol 1991;26:119-123.
26. Reichen J, Widmer T, Cotting J: Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model. Hepatology 1991:14:504-510.
27. V. Schönfeld J, Zotz R, Mahl M, Beste M, Breuer N, Goebell H: Primär sklerosierende Cholangitis: Konventionelle und quantitative Leberfunktionstests unter einer mehrjährigen Therapie mit Ursodcsoxycholsäure. Z Gastroenterol 1996:34:123-127.